NASDAQ:TNXP - Tonix Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Tonix Pharmaceuticals Holding Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.63 +0.24 (+17.27 %) (As of 01/24/2020 04:00 PM ET) Add Compare Today's Range$1.52Now: $1.63▼$1.9850-Day Range$0.92MA: $1.26▼$1.6452-Week Range$0.86Now: $1.63▼$42.00Volume14.96 million shsAverage Volume1.43 million shsMarket Capitalization$10.12 millionP/E RatioN/ADividend YieldN/ABeta1.03 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense. Its lead product candidate is Tonmyar (TNX-102 SL), a proprietary low-dose cyclobenzaprine and sublingual tablet as a bedtime administration, which is in Phase III development for the treatment of posttraumatic stress disorder (PTSD) and Fibromyalgia; and Phase II development for the treatment of agitation in Alzheimer's disease. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TNXP Previous Symbol CUSIPN/A CIK1430306 Webhttp://www.tonixpharma.com/ Phone212-980-9155Debt Debt-to-Equity Ratio0.01 Current Ratio4.88 Quick Ratio4.88Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$72.79 per share Price / Book0.02Profitability EPS (Most Recent Fiscal Year)($268.10) Net Income$-26,090,000.00 Net MarginsN/A Return on Equity-171.46% Return on Assets-149.41%Miscellaneous Employees12 Outstanding Shares6,210,000Market Cap$10.12 million Next Earnings Date3/16/2020 (Estimated) OptionableOptionable Receive TNXP News and Ratings via Email Sign-up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:TNXP Rates by TradingView Tonix Pharmaceuticals (NASDAQ:TNXP) Frequently Asked Questions What is Tonix Pharmaceuticals' stock symbol? Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP." When did Tonix Pharmaceuticals' stock split? How did Tonix Pharmaceuticals' stock split work? Tonix Pharmaceuticals shares reverse split on Wednesday, November 28th 2018. The 1-10 reverse split was announced on Tuesday, November 27th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 27th 2018. An investor that had 100 shares of Tonix Pharmaceuticals stock prior to the reverse split would have 10 shares after the split. How were Tonix Pharmaceuticals' earnings last quarter? Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) issued its quarterly earnings results on Friday, November, 8th. The company reported ($5.69) earnings per share for the quarter, missing analysts' consensus estimates of ($4.35) by $1.34. View Tonix Pharmaceuticals' Earnings History. When is Tonix Pharmaceuticals' next earnings date? Tonix Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Tonix Pharmaceuticals. What price target have analysts set for TNXP? 1 brokerages have issued 1 year price targets for Tonix Pharmaceuticals' stock. Their forecasts range from $1.30 to $1.30. On average, they anticipate Tonix Pharmaceuticals' stock price to reach $1.30 in the next twelve months. This suggests that the stock has a possible downside of 17.2%. View Analyst Price Targets for Tonix Pharmaceuticals. What is the consensus analysts' recommendation for Tonix Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tonix Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tonix Pharmaceuticals. Has Tonix Pharmaceuticals been receiving favorable news coverage? Media stories about TNXP stock have been trending somewhat negative on Friday, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Tonix Pharmaceuticals earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Tonix Pharmaceuticals. Are investors shorting Tonix Pharmaceuticals? Tonix Pharmaceuticals saw a drop in short interest in December. As of December 31st, there was short interest totalling 103,200 shares, a drop of 66.6% from the December 15th total of 309,300 shares. Based on an average daily trading volume, of 1,490,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 1.2% of the company's shares are sold short. View Tonix Pharmaceuticals' Current Options Chain. Who are some of Tonix Pharmaceuticals' key competitors? Some companies that are related to Tonix Pharmaceuticals include Unum Therapeutics (UMRX), Spring Bank Pharmaceuticals (SBPH), Pulmatrix (PULM), Vistagen Therapeutics (VTGN), Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM), Aptevo Therapeutics (APVO), Generex Biotechnology (GNBT), Addex Therapeutics (ADDXF), Akari Therapeutics (AKTX), Fibrocell Science (FCSC), AzurRx BioPharma (AZRX), VIVUS (VVUS), Dare Bioscience (DARE), Bellerophon Therapeutics (BLPH) and Kazia Therapeutics (KZIA). What other stocks do shareholders of Tonix Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tonix Pharmaceuticals investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Actinium Pharmaceuticals (ATNM), Sorrento Therapeutics (SRNE), Synthetic Biologics (SYN), Opko Health (OPK), AVEO Pharmaceuticals (AVEO) and Anavex Life Sciences (AVXL). Who are Tonix Pharmaceuticals' key executives? Tonix Pharmaceuticals' management team includes the folowing people: Dr. Seth Lederman, Co-Founder, Pres, CEO & Chairman (Age 61)Mr. Bradley Saenger, CFO & Treasurer (Age 45)Dr. Gregory M. Sullivan, Chief Medical Officer & Sec. (Age 53)Mrs. Jessica Edgar Morris, Chief Operating OfficerDr. Ronald R. Notvest Ph.D., MBA, Exec. VP of Commercial Planning and Devel. How do I buy shares of Tonix Pharmaceuticals? Shares of TNXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Tonix Pharmaceuticals' stock price today? One share of TNXP stock can currently be purchased for approximately $1.57. How big of a company is Tonix Pharmaceuticals? Tonix Pharmaceuticals has a market capitalization of $9.75 million. The company earns $-26,090,000.00 in net income (profit) each year or ($268.10) on an earnings per share basis. Tonix Pharmaceuticals employs 12 workers across the globe.View Additional Information About Tonix Pharmaceuticals. What is Tonix Pharmaceuticals' official website? The official website for Tonix Pharmaceuticals is http://www.tonixpharma.com/. How can I contact Tonix Pharmaceuticals? Tonix Pharmaceuticals' mailing address is 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022. The company can be reached via phone at 212-980-9155 or via email at [email protected] MarketBeat Community Rating for Tonix Pharmaceuticals (NASDAQ TNXP)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 284 (Vote Outperform)Underperform Votes: 212 (Vote Underperform)Total Votes: 496MarketBeat's community ratings are surveys of what our community members think about Tonix Pharmaceuticals and other stocks. Vote "Outperform" if you believe TNXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TNXP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/24/2020 by MarketBeat.com StaffFeatured Article: What is the Rule of 72?
